Simona Bramante

Publications35
h-index11
Citations484
Highly Influential Citations25
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Akseli Hemminki
  • 311 Publications, 14,328 Citations
  • A. Kanerva
  • 164 Publications, 5,649 Citations
  • V. Cerullo
  • 128 Publications, 3,873 Citations
  • S. Pesonen
  • 94 Publications, 3,115 Citations
  • Publications
  • Influence
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Oncolytic adenovirus is an attractive platform for immunotherapy because virus replication is highly immunogenic and not subject to tolerance. Although oncolysis releases tumor epitopes and provides… Expand
  • 130
  • 6
  • PDF
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and immunogenic cancer cell death. We hypothesized that the combination of oncolytic adenovirus with low-dose temozolomide… Expand
  • 120
  • 5
Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability
Uterine leiomyomas (ULs) are benign tumors that are a major burden to women’s health. A genome-wide association study on 15,453 UL cases and 392,628 controls was performed, followed by replication of… Expand
  • 18
  • 3
  • PDF
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
ABSTRACT Breast cancer is a heterogeneous disease, characterized by several distinct biological subtypes, among which triple-negative breast cancer (TNBC) is one associated with a poor prognosis.… Expand
  • 16
  • 2
  • PDF
Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
In clinical trials with oncolytic adenoviruses, there has been no mortality associated with treatment vectors. Likewise, in the Advanced Therapy Access Program (ATAP), where 290 patients were treated… Expand
  • 19
  • 2
Produced by a CD 40 L-Encoding Oncolytic Adenovirus Immune Response Is an Important Aspect of the Antitumor Effect
Oncolytic adenovirus is an attractive platform for immunotherapy because virus replication is highly immunogenic and not subject to tolerance. Although oncolysis releases tumor epitopes and provides… Expand
  • 5
  • 2
  • PDF
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Adoptive T-cell transfer is a promising treatment approach for metastatic cancer, but efficacy in solid tumors has only been achieved with toxic pre- and postconditioning regimens. Thus, adoptive… Expand
  • 24
  • 1
  • PDF
Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans
Sarcomas are a relatively rare cancer, but often incurable at the late metastatic stage. Oncolytic immunotherapy has gained attention over the past years, and a wide range of oncolytic viruses have… Expand
  • 32
  • 1
  • PDF
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans
Metastatic melanoma is refractory to irradiation and chemotherapy, but amenable to immunological approaches such as immune‐checkpoint‐inhibiting antibodies or adoptive cell therapies. Oncolytic virus… Expand
  • 30
  • 1
  • PDF
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
About this supplement These abstracts have been published as part of Journal for ImmunoTherapy of Cancer Volume 4 Suppl 1, 2016. The full contents of the supplement are available online at… Expand
  • 9
  • 1